Skip to main content
EVAX
NASDAQ Life Sciences

Evaxion Refocuses on Cancer Vaccines as Q3 Loss Narrows to $3.5M, Cash Runway to Late 2027

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.819
Mkt Cap
$21.184M
52W Low
$2.425
52W High
$6.92
52W Position info
16% above low
Off High info
59% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

EVAX sits 16% above its 52-week low of $2.425.

Summary

Evaxion is narrowing its pipeline to immuno-oncology, prioritizing off-the-shelf cancer vaccines EVX-04 and EVX-05 and pushing EVX-01 into more indications through partnerships. Infectious disease and autoimmune work will only continue with external partner funding, and the company said it will make organizational adjustments as a result. Q3 2026 net loss was $3.5 million, or a loss of 1 cent per share, versus a $3.7 million loss in Q2 and a $4.6 million profit a year ago, when revenue came from out-licensing EVX-B3 to MSD; no revenue was booked this quarter. Cash stood at $13.3 million at September 30, down from $14.0 million at June 30, with the runway extended toward the end of 2027 after $2.2 million in gross ATM proceeds. The near-term milestone is the EVX-04 phase 1 trial application, targeted before year-end, with target validation data due at ASH December 12-15.

Updates

  1. · SEC 6-K — Evaxion's Q3 2026 R&D expenses were $2.3 million and G&A $1.4 million; total equity fell to $8.1 million from $17.0 million at December 31, 2025.

At the time of this announcement, EVAX was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $2.43 to $6.92. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

EVAX - Latest Insights

EVAX
Nov 19, 2026, 7:05 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $2.58 info
Change: +$0.0373 (+1%) info
Market Cap: $21.184M info
EVAX
Oct 23, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.58 info
Change: -$1.46 (-36%) info
Market Cap: $21.184M info
EVAX
Oct 19, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.58 info
Change: -$0.6727 (-21%) info
Market Cap: $21.184M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $2.58 info
Change: -$0.8927 (-26%) info
Market Cap: $21.184M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $2.58 info
Change: -$0.8977 (-26%) info
Market Cap: $21.184M info